izpis_h1_title_alt

Co-crystals, salts or mixtures of both? The case of tenofovir alafenamide fumarates
ID Lengauer, Hannes (Avtor), ID Makuc, Damjan (Avtor), ID Šterk, Damjan (Avtor), ID Perdih, Franc (Avtor), ID Pichler, Arthur (Avtor), ID Trdan Lušin, Tina (Avtor), ID Plavec, Janez (Avtor), ID Časar, Zdenko (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (3,70 MB)
MD5: 6C0109C8703ACBEF8083424FF92F68A4
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/1999-4923/12/4/342 Povezava se odpre v novem oknu

Izvleček
Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated and described in the literature, there are no data in the scientific literature on the solid state properties of TAF. In our report, we describe the preparation of two novel polymorphs II and III of tenofovir alafenamide monofumarate (TA MF2 and TA MF3). The solid-state structure of these compounds was investigated in parallel to the previously known tenofovir alafenamide monofumarate form I (TA MF1) and tenofovir alafenamide hemifumarate (TA HF). Interestingly, the single-crystal X-ray diffraction of TA HF revealed that this derivative exists as a co-crystal form. In addition, we prepared a crystalline tenofovir alafenamide free base (TA) and its hydrochloride salt (TA HCl), which enabled us to determine the structure of TA MF derivatives using $^{15}$N-ssNMR ($^{15}$N-solid state nuclear magnetic resonance). Surprisingly, we observed that TA MF1 exists as a mixed ionization state complex or pure salt, while TA MF2 and TA MF3 can be obtained as pure co-crystal forms.

Jezik:Angleški jezik
Ključne besede:co-crystal, salt, polymorphism, X-ray diffraction, ssNMR, tenofovir alafenamide fumarate
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:FKKT - Fakulteta za kemijo in kemijsko tehnologijo
FFA - Fakulteta za farmacijo
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2020
Št. strani:21 str.
Številčenje:Vol. 12, iss. 4, art. 342
PID:20.500.12556/RUL-133367 Povezava se odpre v novem oknu
UDK:615
ISSN pri članku:1999-4923
DOI:10.3390/pharmaceutics12040342 Povezava se odpre v novem oknu
COBISS.SI-ID:1569374 Povezava se odpre v novem oknu
Datum objave v RUL:24.11.2021
Število ogledov:865
Število prenosov:121
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Pharmaceutics
Skrajšan naslov:Pharmaceutics
Založnik:MDPI
ISSN:1999-4923
COBISS.SI-ID:517949977 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:10.04.2020

Projekti

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Lek/Sandoz

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj